S&P Futures
3,765.75 -55.50 (-1.45%) Dow Futures
30,616.00 -383.00 (-1.24%) Nasdaq Futures
11,492.50 -198.50 (-1.70%) Russell 2000 Futures
1,695.00 -26.40 (-1.53%) Crude Oil
109.21 -0.57 (-0.52%) Gold
1,817.30 -0.20 (-0.01%)
BioNTech SE (BNTX)
After hours:
Chart Events
Performance Outlook
| Previous Close | 139.82 |
| Open | 139.64 |
| Bid | 0.00 x 1000 |
| Ask | 0.00 x 800 |
| Day's Range | 137.02 - 143.25 |
| 52 Week Range | 117.08 - 464.00 |
| Volume | |
| Avg. Volume | 1,327,490 |
| Market Cap | 34.504B |
| Beta (5Y Monthly) | -0.29 |
| PE Ratio (TTM) | 2.79 |
| EPS (TTM) | 50.87 |
| Earnings Date | Aug 08, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Jun 02, 2022 |
| 1y Target Est | 252.86 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for BNTX
Related Research
- BioNTech SEAnalyst Report: BioNTech SEBioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and small-molecule immunomodulators. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Comirnaty (COVID-19 vaccine) is its first commercialized product.RatingFair ValueEconomic MoatyesterdayMorningstar
- Editor's PickYahoo Finance Video
FDA recommends updating COVID booster shots to fight Omicron
Yahoo Finance's Anjalee Khemlani joins the Live show to discuss the FDA's vote to update its COVID-19 boosters.
- The Wall Street Journal
U.S. Agrees to Pay $3.2 Billion for More Pfizer Covid Vaccines
Under the deal, the U.S. government will get 105 million doses and have the option to purchase more. The doses would be for a fall booster drive.
- MarketWatch
U.S. to pay $3.2 billion to Pfizer, BioNTech for more COVID-19 vaccines for fall
Pfizer Inc. and BioNTech SE said late Wednesday they have inked a new agreement with the U.S. government to supply 105 million doses of their COVID-19 vaccines, including a formulation adapted to target omicron variants, pending approval from the FDA. The two pharma companies said the doses are expected to be delivered as soon as late summer, and continue into the end of the year. Under the agreement, the U.S. has the option to buy up to 195 million additional doses, which would bring the total
